Shuang Ye - Search Results

Year	Number of Results
2003	1
2004	1
2005	1
2006	5
2007	6
2008	4
2010	1
2011	4
2012	5
2013	4
2014	11
2015	13
2016	5
2017	12
2018	15
2019	26
2020	20
2021	24
2022	35
2023	26
2024	9

1

Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, Chen Z, Ye S. Wu W, et al. Among authors: ye s. Clin Rev Allergy Immunol. 2021 Apr;60(2):293-304. doi: 10.1007/s12016-020-08822-5. Epub 2021 Jan 6. Clin Rev Allergy Immunol. 2021. PMID: 33405101 Review.

2

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

Chen Z, Wang X, Ye S. Chen Z, et al. Among authors: ye s. N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045. N Engl J Med. 2019. PMID: 31314977 Clinical Trial. No abstract available.

3

Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications.

Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X, Xue J, Lian X, Ma J, Hao P, Lu L, Ye S, Shen N, Bao C, Fu Q, Zhang X. Ye Y, et al. Among authors: ye s. Nat Commun. 2022 Oct 29;13(1):6458. doi: 10.1038/s41467-022-34145-4. Nat Commun. 2022. PMID: 36309526 Free PMC article.

4

Editorial: Anti-MDA5-Positive Dermatomyositis.

Gono T, Ye S, Han Q. Gono T, et al. Among authors: ye s. Front Med (Lausanne). 2022 May 31;9:941370. doi: 10.3389/fmed.2022.941370. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35712109 Free PMC article. No abstract available.

5

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.

Sun F, Lin Y, Wang X, Gao Y, Ye S. Sun F, et al. Among authors: ye s. Lancet Infect Dis. 2022 Sep;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3. Epub 2022 Jul 14. Lancet Infect Dis. 2022. PMID: 35843259 Free PMC article. No abstract available.

6

Inflammatory Joint Diseases.

Shi G, Ambrus JL, Ye S, Shen L. Shi G, et al. Among authors: ye s. Biomed Res Int. 2015;2015:973510. doi: 10.1155/2015/973510. Epub 2015 May 21. Biomed Res Int. 2015. PMID: 26090466 Free PMC article. No abstract available.

7

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.

Wang H, Li T, Sun F, Liu Z, Zhang D, Teng X, Morel L, Wang X, Ye S. Wang H, et al. Among authors: ye s. RMD Open. 2022 Oct;8(2):e002686. doi: 10.1136/rmdopen-2022-002686. RMD Open. 2022. PMID: 36288823 Free PMC article. Clinical Trial.

8

Reply.

Teng X, Liu Z, Wang H, Ye S. Teng X, et al. Among authors: ye s. Arthritis Rheumatol. 2016 Dec;68(12):3043. doi: 10.1002/art.39864. Arthritis Rheumatol. 2016. PMID: 27636588 No abstract available.

9

Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study.

Zhang L, Li J, Yin H, Chen D, Li Y, Gu L, Fu Y, Chen J, Chen Z, Yang S, Ye S, Li T, Lu L. Zhang L, et al. Among authors: ye s. Ann Rheum Dis. 2023 May;82(5):722-724. doi: 10.1136/ard-2022-223562. Epub 2023 Jan 5. Ann Rheum Dis. 2023. PMID: 36604153 Free PMC article. Clinical Trial. No abstract available.

10

Still bizarre.

Zhou L, Chen Y, Ye S. Zhou L, et al. Among authors: ye s. J Clin Rheumatol. 2012 Jan;18(1):56. doi: 10.1097/RHU.0b013e31823ee8db. J Clin Rheumatol. 2012. PMID: 22198487 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

201 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year